Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Monopar Therapeutics changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 14 | 16 | +2 |
| Shares | 271.4K | 395.3K | +123.9K (+45.7%) |
| Value | $91.7K | $268.1K | +$176.3K (+192.3%) |
New holders (5)
Institutions that held Monopar Therapeutics at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 32,113 | $21.0K | 0.00% |
| FMR LLC | 5,500 | $3.75K | 0.00% |
| GWM Advisors LLC | 3,000 | $2.04K | 0.00% |
| Bank of America Corp | 500 | $340 | 0.00% |
| Royal Bank of Canada | 100 | $0 | 0.00% |
Sold out (3)
Institutions that held Monopar Therapeutics at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Renaissance Technologies LLC | 48,086 | $16.0K |
| Two Sigma Investments, LP | 14,302 | $4.87K |
| Susquehanna International Group, LLP | 10,993 | $3.74K |